MRSA decolonization kit trial stalls after just one patient
NCT ID NCT05696132
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a complete kit using povidone-iodine (Betadine) gel, soap, and mouthwash to clear MRSA bacteria from patients' noses, skin, and mouths. The goal was to see if the kit could quickly decolonize MRSA within 6 hours. However, the trial was terminated early after enrolling only one participant, so no reliable results are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- povidone-iodine (Betadine) gel, antiseptic soap, and mouthwash
- What this could lead to
- If it worked, this could offer an alternative to standard MRSA decolonization treatments that are facing drug resistance.
- What could go wrong
- The trial was terminated early with only 1 participant, so no meaningful conclusions can be drawn. Povidone-iodine may not effectively clear MRSA from all body sites in real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
1 person
The number who actually took part.
- Started
-
Nov 2024
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients readmitted at the Nantes University Hospital and detected to be already MRSA positive by nasal systematic screening, * MRSA patients with length of hospital stay \> 4 days * Patient older than 18 years and informed about the study, * Patients who provide their written informed consent, * Patient affiliated with French social security system or beneficiary from such system. Women must meet one of the following criteria at the time of inclusion: * use adequate contraceptive measures as recommended by the CTFG (Recommendations related to contraception and pregnancy testing in clinical trials v1.1), and have a negative pregnancy test (urine test) prior to receiving the first dose of study drug; * or be post-menopausal (over 50 years of age with amenorrhea for at least 12 months after discontinuation of all exogenous hormonal therapy) * or (if under 50 years of age) have been amenorrheic for at least 12 months after discontinuation of exogenous hormonal therapy and with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels corresponding to post-menopausal levels * or have undergone irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy (this operation must be documented). Exclusion Criteria: * Patient \< 18 years, * Patient with known intolerance to PVD-I derivatives or excipients * Known MRSA colonized patient managed in outpatient or inpatient care but with a negative nasal screen, * New patient with MRSA infection (this patient can be included later in case of hospital readmission), * Pregnancy or breastfeeding, patient with childbearing potential that refused acceptable contraceptive method * Patients with a known risk of allergy to povidone iodine, * Patients with damaged skin or mucous, * Patients with a history of thyroid disorders, * Adults under guardianship or trusteeship, * Patients under juridical protection * Use of mercurial antiseptic during the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MRSA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nantes
Nantes, 44093, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.